116 related articles for article (PubMed ID: 10532238)
1. A convergent liquid-phase synthesis of salmon calcitonin.
Lee YS; Lee HJ; Pozdnyakov PI; Samukov VV; Kim HJ
J Pept Res; 1999 Oct; 54(4):328-35. PubMed ID: 10532238
[TBL] [Abstract][Full Text] [Related]
2. Transdermal iontophoresis of salmon calcitonin can reproduce the hypocalcemic effect of intravenous administration.
Santi P; Volpato NM; Bettini R; Catellani PL; Massimo G; Colombo P
Farmaco; 1997; 52(6-7):445-8. PubMed ID: 9372596
[TBL] [Abstract][Full Text] [Related]
3. Comparison of reversible and nonreversible aqueous-soluble lipidized conjugates of salmon calcitonin.
Cheng W; Lim LY
Mol Pharm; 2008; 5(4):610-21. PubMed ID: 18481870
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of the partially protected fragment 1-16 of salmon calcitonin by using the phenylhydrazide protecting group.
Semenov AN; Lomonosova IV
Int J Pept Protein Res; 1994 Feb; 43(2):113-7. PubMed ID: 8200728
[TBL] [Abstract][Full Text] [Related]
5. Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Taylor JW; Jin QK; Sbacchi M; Wang L; Belfiore P; Garnier M; Kazantzis A; Kapurniotu A; Zaratin PF; Scheideler MA
J Med Chem; 2002 Feb; 45(5):1108-21. PubMed ID: 11855991
[TBL] [Abstract][Full Text] [Related]
6. Lipeo-sCT: a novel reversible lipidized salmon calcitonin derivative, its biophysical properties and hypocalcemic activity.
Cheng W; Lim LY
Eur J Pharm Sci; 2009 May; 37(2):151-9. PubMed ID: 19429422
[TBL] [Abstract][Full Text] [Related]
7. [Synthesis of a partially purified fragment of salmon calcitonin 1-16 using a phenylhydrazide protective group].
Semenov AN; Lomonosova IV
Bioorg Khim; 1993 Feb; 19(2):182-9. PubMed ID: 8498959
[TBL] [Abstract][Full Text] [Related]
8. Amino acid sequence of sardine calcitonin and its hypocalcemic activity in rats.
Suzuki N; Nosé Y; Kasé Y; Sasayama Y; Takei Y; Nagasawa H; Watanabe TX; Nakajima K; Sakakibara S
Zoolog Sci; 1994 Oct; 11(5):713-6. PubMed ID: 7765857
[TBL] [Abstract][Full Text] [Related]
9. Goldfish calcitonin: purification, characterization, and hypocalcemic potency.
Sasayama Y; Ukawa K; Kai-Ya H; Oguro C; Takei Y; Watanabe TX; Nakajima K; Sakakibara S
Gen Comp Endocrinol; 1993 Feb; 89(2):189-94. PubMed ID: 8454163
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic evaluation of the calcitonin analogue SB 205614 in models of osteoclastic bone resorption in vitro and in vivo: comparison with salmon calcitonin and elcatonin.
McSheehy PM; Farina C; Airaghi R; Allievi E; Banfi S; Bertolini D; Ferni G; Frattola D; Oneta S; Pinza M
Bone; 1995 Apr; 16(4):435-44. PubMed ID: 7605704
[TBL] [Abstract][Full Text] [Related]
11. The biological potency of a series of analogues of human calcitonin correlates with their interactions with phospholipids.
Epand RF; Orlowski RC; Epand RM
Biopolymers; 2004; 76(3):258-65. PubMed ID: 15148685
[TBL] [Abstract][Full Text] [Related]
12. Calcitonin of the stingray: comparison of the hypocalcemic activity with other calcitonins.
Sasayama Y; Suzuki N; Oguro C; Takei Y; Takahashi A; Watanabe TX; Nakajima K; Sakakibara S
Gen Comp Endocrinol; 1992 May; 86(2):269-74. PubMed ID: 1601276
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 55% TFA/CH2Cl2 and 100% TFA for Boc group removal during solid-phase peptide synthesis.
Blondelle SE; Houghten RA
Int J Pept Protein Res; 1993 Jun; 41(6):522-7. PubMed ID: 8349409
[TBL] [Abstract][Full Text] [Related]
14. Aqueous-soluble, non-reversible lipid conjugate of salmon calcitonin: synthesis, characterization and in vivo activity.
Cheng W; Satyanarayanajois S; Lim LY
Pharm Res; 2007 Jan; 24(1):99-110. PubMed ID: 17109213
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization and in vivo activity of salmon calcitonin coconjugated with lipid and polyethylene glycol.
Cheng W; Lim LY
J Pharm Sci; 2009 Apr; 98(4):1438-51. PubMed ID: 18704953
[TBL] [Abstract][Full Text] [Related]
16. Conformational requirements for activity of salmon calcitonin.
Findlay DM; Michelangeli VP; Martin TJ; Orlowski RC; Seyler JK
Endocrinology; 1985 Sep; 117(3):801-5. PubMed ID: 4017965
[TBL] [Abstract][Full Text] [Related]
17. Use of 6 M HCl for removal of the N-alpha-tert-butyloxycarbonyl group during solid-phase peptide synthesis.
Naharissoa H; Sarrade V; Follet M; Calas B
Pept Res; 1992; 5(5):293-9. PubMed ID: 1450524
[TBL] [Abstract][Full Text] [Related]
18. Further studies into the Boc/solid-phase synthesis of Ser(P)- and Thr(P)-containing peptides.
Perich JW; Terzi E; Carnazzi E; Seyer R; Trifilieff E
Int J Pept Protein Res; 1994 Oct; 44(4):305-12. PubMed ID: 7875931
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of salmon calcitonin-sodium triphosphate ionic complex for oral delivery.
Lee HE; Lee MJ; Park CR; Kim AY; Chun KH; Hwang HJ; Oh DH; Jeon SO; Kang JS; Jung TS; Choi GJ; Lee S
J Control Release; 2010 Apr; 143(2):251-7. PubMed ID: 20026364
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of peptides using tert-butyloxycarbonyl (Boc) as the α-amino protection group.
Pedersen SW; Armishaw CJ; Strømgaard K
Methods Mol Biol; 2013; 1047():65-80. PubMed ID: 23943478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
